JOHNSON & JOHNSON (1JNJ.MI) Fundamental Analysis & Valuation

BIT:1JNJ • US4781601046

212.85 EUR
+6.8 (+3.3%)
Last: Mar 2, 2026, 07:00 PM

This 1JNJ.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 1JNJ. 1JNJ was compared to 49 industry peers in the Pharmaceuticals industry. 1JNJ scores excellent on profitability, but there are some minor concerns on its financial health. 1JNJ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. 1JNJ.MI Profitability Analysis

1.1 Basic Checks

  • 1JNJ had positive earnings in the past year.
  • 1JNJ had a positive operating cash flow in the past year.
  • Each year in the past 5 years 1JNJ has been profitable.
  • 1JNJ had a positive operating cash flow in each of the past 5 years.
1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCF1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • With an excellent Return On Assets value of 13.46%, 1JNJ belongs to the best of the industry, outperforming 86.54% of the companies in the same industry.
  • 1JNJ has a better Return On Equity (32.87%) than 78.85% of its industry peers.
  • 1JNJ has a better Return On Invested Capital (14.37%) than 71.15% of its industry peers.
  • 1JNJ had an Average Return On Invested Capital over the past 3 years of 16.34%. This is above the industry average of 13.98%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 14.37%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
1JNJ.MI Yearly ROA, ROE, ROIC1JNJ.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • The Profit Margin of 1JNJ (28.46%) is better than 90.38% of its industry peers.
  • In the last couple of years the Profit Margin of 1JNJ has grown nicely.
  • With a decent Operating Margin value of 27.78%, 1JNJ is doing good in the industry, outperforming 73.08% of the companies in the same industry.
  • In the last couple of years the Operating Margin of 1JNJ has grown nicely.
  • The Gross Margin of 1JNJ (67.92%) is comparable to the rest of the industry.
  • 1JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
1JNJ.MI Yearly Profit, Operating, Gross Margins1JNJ.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. 1JNJ.MI Health Analysis

2.1 Basic Checks

  • 1JNJ has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, 1JNJ has about the same amount of shares outstanding.
  • 1JNJ has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 1JNJ has a worse debt to assets ratio.
1JNJ.MI Yearly Shares Outstanding1JNJ.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
1JNJ.MI Yearly Total Debt VS Total Assets1JNJ.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • 1JNJ has an Altman-Z score of 5.10. This indicates that 1JNJ is financially healthy and has little risk of bankruptcy at the moment.
  • 1JNJ has a Altman-Z score of 5.10. This is in the better half of the industry: 1JNJ outperforms 75.00% of its industry peers.
  • 1JNJ has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as 1JNJ would need 2.43 years to pay back of all of its debts.
  • 1JNJ's Debt to FCF ratio of 2.43 is amongst the best of the industry. 1JNJ outperforms 80.77% of its industry peers.
  • 1JNJ has a Debt/Equity ratio of 0.56. This is a neutral value indicating 1JNJ is somewhat dependend on debt financing.
  • 1JNJ has a Debt to Equity ratio (0.56) which is comparable to the rest of the industry.
  • Although 1JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 5.1
ROIC/WACC1.51
WACC9.51%
1JNJ.MI Yearly LT Debt VS Equity VS FCF1JNJ.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • A Current Ratio of 1.03 indicates that 1JNJ should not have too much problems paying its short term obligations.
  • 1JNJ has a Current ratio of 1.03. This is in the lower half of the industry: 1JNJ underperforms 76.92% of its industry peers.
  • A Quick Ratio of 0.77 indicates that 1JNJ may have some problems paying its short term obligations.
  • 1JNJ's Quick ratio of 0.77 is on the low side compared to the rest of the industry. 1JNJ is outperformed by 73.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
1JNJ.MI Yearly Current Assets VS Current Liabilites1JNJ.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

5

3. 1JNJ.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.11% over the past year.
  • 1JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.11% yearly.
  • 1JNJ shows a small growth in Revenue. In the last year, the Revenue has grown by 6.05%.
  • 1JNJ shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.67% yearly.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • 1JNJ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.75% yearly.
  • 1JNJ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.02% yearly.
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1JNJ.MI Yearly Revenue VS Estimates1JNJ.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
1JNJ.MI Yearly EPS VS Estimates1JNJ.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

2

4. 1JNJ.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 23.26 indicates a rather expensive valuation of 1JNJ.
  • The rest of the industry has a similar Price/Earnings ratio as 1JNJ.
  • When comparing the Price/Earnings ratio of 1JNJ to the average of the S&P500 Index (27.03), we can say 1JNJ is valued inline with the index average.
  • 1JNJ is valuated rather expensively with a Price/Forward Earnings ratio of 21.57.
  • 1JNJ's Price/Forward Earnings ratio is in line with the industry average.
  • 1JNJ is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.26
Fwd PE 21.57
1JNJ.MI Price Earnings VS Forward Price Earnings1JNJ.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as 1JNJ.
  • 1JNJ's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 30.73
EV/EBITDA 17.75
1JNJ.MI Per share data1JNJ.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1JNJ does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of 1JNJ may justify a higher PE ratio.
PEG (NY)2.95
PEG (5Y)3.81
EPS Next 2Y8.2%
EPS Next 3Y8.39%

5

5. 1JNJ.MI Dividend Analysis

5.1 Amount

  • 1JNJ has a Yearly Dividend Yield of 2.14%.
  • Compared to an average industry Dividend Yield of 1.84, 1JNJ pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, 1JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.14%

5.2 History

  • On average, the dividend of 1JNJ grows each year by 7.68%, which is quite nice.
Dividend Growth(5Y)7.68%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1JNJ pays out 46.19% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • 1JNJ's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
1JNJ.MI Yearly Income VS Free CF VS Dividend1JNJ.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
1JNJ.MI Dividend Payout.1JNJ.MI Dividend Payout, showing the Payout Ratio.1JNJ.MI Dividend Payout.PayoutRetained Earnings

1JNJ.MI Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

BIT:1JNJ (3/2/2026, 7:00:00 PM)

212.85

+6.8 (+3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap512.82B
Revenue(TTM)94.19B
Net Income(TTM)26.80B
Analysts75.63
Price Target197.11 (-7.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.14%
Yearly Dividend4.36
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)8.42%
PT rev (3m)12.23%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)-3.15%
EPS NY rev (1m)0.79%
EPS NY rev (3m)-0.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE 23.26
Fwd PE 21.57
P/S 6.43
P/FCF 30.73
P/OCF 24.68
P/B 7.42
P/tB N/A
EV/EBITDA 17.75
EPS(TTM)9.15
EY4.3%
EPS(NY)9.87
Fwd EY4.64%
FCF(TTM)6.93
FCFY3.25%
OCF(TTM)8.62
OCFY4.05%
SpS33.12
BVpS28.67
TBVpS-6.2
PEG (NY)2.95
PEG (5Y)3.81
Graham Number76.83
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.03%
ROIC 14.37%
ROICexc 16.57%
ROICexgc 67.45%
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
ROICexc(3y)19.6%
ROICexc(5y)18.23%
ROICexgc(3y)74.51%
ROICexgc(5y)73.44%
ROCE(3y)20.24%
ROCE(5y)18.7%
ROICexgc growth 3Y3.9%
ROICexgc growth 5Y-2.01%
ROICexc growth 3Y8.52%
ROICexc growth 5Y5.62%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.36
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 6.81
Cash Conversion 72.86%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 5.1
F-Score4
WACC9.51%
ROIC/WACC1.51
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%
EBIT growth 1Y12.82%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.18%
EBIT Next 3Y11.51%
EBIT Next 5Y8.55%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / 1JNJ.MI FAQ

What is the fundamental rating for 1JNJ stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI.


What is the valuation status of JOHNSON & JOHNSON (1JNJ.MI) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (1JNJ.MI). This can be considered as Overvalued.


Can you provide the profitability details for JOHNSON & JOHNSON?

JOHNSON & JOHNSON (1JNJ.MI) has a profitability rating of 7 / 10.


What is the valuation of JOHNSON & JOHNSON based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JOHNSON & JOHNSON (1JNJ.MI) is 23.26 and the Price/Book (PB) ratio is 7.42.


What is the financial health of JOHNSON & JOHNSON (1JNJ.MI) stock?

The financial health rating of JOHNSON & JOHNSON (1JNJ.MI) is 5 / 10.